Skip to main content
Premium Trial:

Request an Annual Quote

OncoMethylome Sciences' Q1 Revenues Decline; Cuts Loss

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – OncoMethylome Sciences this week reported that its first-quarter revenues fell 8 percent on lower grant revenues, but the firm still managed to cut its net loss for the quarter.

The Liege, Belgium-based molecular diagnostics developer had total revenues of €634,000 ($802,400) for the three-month period ended March 31, compared to €688,000 for the first quarter of 2009. Though it didn't break out its revenue sources, the firm said that a reduction in grant revenue was offset by an increase in commercial revenues.

OncoMethylome's net loss for the quarter was €2.4 million versus €2.9 million for Q1 2009.

The company said that as of the end of 2009 it has focused its development efforts on its diagnostic programs in colorectal, bladder, and prostate cancers, as well as pharmacogenomics.

OncoMethylome finished the quarter with €16.1 million in cash and cash equivalents.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.